Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA by Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A

Get full text

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal by Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B

Get full text

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol by Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF

Get full text

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone by Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G

Get full text

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corri... by Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G

Get full text

Current controversies in chronic obstructive pulmonary disease. A report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee by Criner, GJ, Martinez, FJ, Aaron, S, Agusti, A, Anzueto, A, Bafadhel, M, Barnes, PJ, Bourbeau, J, Chen, R, Ewig, J, Fabbri, LM, Frith, P, Halpin, DMG, Han, M, De Oca, M, Nishimura, M, O'Donnell, D, Papi, A, Pavord, I, Roche, N, Rodriguez-Roisin, R, Salvi, S, Singh, D, Sin, DD, Stockley, R, Varela, MV, Vestbo, J, Vogelmeier, CF, Washko, G, Wedzicha, JA, Celli, BR